NDA 203155 · Mcprf
Choline C-11
Choline C-11 · Intravenous · Radioactive Diagnostic Agent
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Sep 12, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
11
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 26, 2025.
Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration. Limitation of U se: 11 C-choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer. Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging. In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration. Limitation of U se: 11 C-choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer ( 1 ).
Mechanism: Choline C 11 Injection is a radiolabeled analog of choline, a precursor molecule essential for the biosynthesis of cell membrane phospholipids. Choline is involved in synthesis of the structural components of cell membranes, as well as modulation of trans-membrane signaling. Increased phospholipid synthesis (i.e., increased uptake of choline) has been associated with cell proliferation and the transformation process that occurs in tumor cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 12, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewSummary ReviewLetter
1 products under this application
- CHOLINE C-11 · CHOLINE C-11 4-33.1mCi/ML · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Choline C-11" as an intervention, any sponsor and status, largest first.
Mayo ClinicAcademic, hospital or other
NCT03768349 · 250 participants · Start Jan 3, 2019 · Primary completion Jul 21, 2021
Drug: Ga-68 PSMA11; F-18 PSMA 1007 · For: Prostate Cancer
Sites: Rochester, Minnesota
- Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate CancerPivotal-lookingCompleted
Global Isotopes, LLC d/b/a Zevacor MolecularIndustry
NCT02260817 · 109 participants · Start Oct 2014 · Primary completion Jun 2016
Drug: 11C-choline Injection · For: Metastatic Prostate Cancer
Sites: Decatur, Illinois
Chang Gung Memorial HospitalAcademic, hospital or other
NCT02852122 · 54 participants · Start Jan 2015 · Primary completion Dec 2016
Drug: C-11 choline · For: Latent Cancer Prostate
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT04560725 · 50 participants (planned) · Start Oct 22, 2020 · Primary completion Dec 1, 2024
Drug: 11C-Choline · For: Prostate Cancer
Sites: Beijing, China
- Characterizing LAM With 11C-Choline PET/CTStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT05087134 · 50 participants (planned) · Start Nov 2021 · Primary completion Sep 2022
Drug: 11C-Choline · For: Lymphangioleiomyomatosis
Sites: Beijing, China
Commissariat A L'energie AtomiqueGovernment (non-federal)
NCT01377220 · 30 participants (planned) · Start Jun 2011 · Primary completion Jun 2013
Drug: 11C-Choline · For: Hepatocellular Carcinoma
Sites: Orsay, France
- A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal CancerCompleted
Wake Forest University Health SciencesAcademic, hospital or other
NCT01051479 · 22 participants · Start Mar 2010 · Primary completion Aug 2013
Drug: C11-Choline · For: Esophageal Cancer
Sites: Winston-Salem, North Carolina
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT04693169 · 20 participants (planned) · Start Jan 15, 2021 · Primary completion Jun 12, 2024
Drug: 11C-Choline · For: Prostate Cancer
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Mcprf
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.